CM
BPMC

Castleark Management’s Blueprint Medicines BPMC Stock Holding History

Castleark Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-33,990
Closed -$3.14M – 291
2024
Q3 		$3.14M Sell
33,990
-5,450
-14% -$541K 0.13% 148
2024
Q2 		$4.25M Buy
+39,440
New +$3.95M 0.17% 132

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Castleark Management's BPMC Position: Q4 2024 in Review

Castleark Management sold out of Blueprint Medicines (BPMC) in Q4 2024, closing a stake of 33,990 shares — an estimated $3.14M sold.

Castleark Management first reported a position in BPMC in Q2 2024 and held it in 2 quarters. The position peaked at $4.25M in Q2 2024. 345 funds tracked by Wall St. Rank hold BPMC as of Q4 2024.

  • Castleark Management reported no remaining Blueprint Medicines position as of Q4 2024 after selling out during the quarter.
  • Castleark Management sold 33,990 Blueprint Medicines shares in Q4 2024, an estimated $3.14M.
  • Castleark Management first reported a position in Blueprint Medicines in Q2 2024 and held it in 2 quarters.
  • Castleark Management's Blueprint Medicines position peaked at $4.25M in Q2 2024.
  • 345 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2024.

Based on Castleark Management's 13F filing for Q4 2024, filed 18 Feb 2025.